# Evelo Biosciences plunges 43% premarket as the Co. to review options after Phase 2 trial of psoriasis treatment fails to meet main goal
**FDA Update**

**2023-10-17 13:03**

**https://www.ainvest.com/news/evelo-biosciences-plunges-43-premarket-as-co-to-review-options-after-phase-2-trial-of-psoriasis-treatment-fails-to-meet-main-goal-23101000cac545f480852f65/**

Evelo Biosciences plunges 43% premarket as the Co. to review options after Phase 2 trial of psoriasis treatment fails to meet main goal